Impact of HCV eradication following direct-acting antivirals on liver stiffness measurement: a prospective longitudinal study

Egyptian Liver Journal

Table 3 Mean percent decrease of liver stiffness within each liver stiffness category according to demographic data using Wilcoxon signed-rank test

Liver stiffness	Variables	Patients groups	Number	Mean percent Liver stiffness change (%)	p-value*
< 10 kPa	Age	≤ 50 years	n = 23	− 25.69%	0.528
	Age	> 50 years	n = 31	− 20.37%	0.528
	Sex	Male	n = 27	− 21.17%	0.728
	Sex	Female	n = 27	− 24.11%	0.728
	Diabetes	Nondiabetic	n = 40	− 19.71%	0.214
	Diabetes	Diabetic	n = 14	− 30.44%	0.214
	BMI	BMI < 25	n = 16	− 30.74%	0.944
	BMI	BMI > 25	n = 38	− 30.84%	0.944
10–15 kPa	Age	≤ 50	n = 5	− 18.59%	0.198
	Age	> 50	n = 12	− 11.39%	0.198
	Sex	Male	n = 9	− 18.64%	0.769
	Sex	Female	n = 8	− 7.73%	0.769
	Diabetes	Nondiabetic	n = 14	− 22.93%	0.420
	Diabetes	Diabetic	n = 3	− 10.96%	0.420
	BMI	BMI < 25	n = 9	− 39.38%	0.879
	BMI	BMI > 25	n = 8	− 39.59%	0.879
> 15 kPa	Age	≤ 50	n = 13	− 22.72%	0.397
	Age	> 50	n = 19	− 36.60%	0.397
	Sex	Male	n = 14	− 26.88%	0.614
	Sex	Female	n = 18	− 34.14%	0.614
	Diabetes	Nondiabetic	n = 27	− 30.63%	0.940
	Diabetes	Diabetic	n = 5	− 28.92%	0.940
	BMI	BMI < 25	n = 11	− 33.33%	0.318
	BMI	BMI > 25	n = 21	− 31.14%	0.318